Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Xilio Therapeutics, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 31
- −2 vs. Q4 2023
- Shares held
- 12.5M
- −3.71M (−22.9%) vs. Q4 2023
- Total value
- $13.5M
- +$4.58M (+51.5%) vs. Q4 2023
- New holders
- 6
- 5 more added
- Sold out
- 8
- 5 more reduced
1 institution that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XLO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $32.6M |
| Q1 2026 | 24 | $22.0M |
| Q4 2025 | 37 | $25.4M |
| Q3 2025 | 36 | $18.6M |
| Q2 2025 | 35 | $16.2M |
| Q1 2025 | 35 | $16.3M |
| Q4 2024 | 35 | $24.7M |
| Q3 2024 | 33 | $12.6M |
| Q2 2024 | 32 | $13.7M |
| Q1 2024 | 31 | $13.5M |
| Q4 2023 | 34 | $9.03M |
| Q3 2023 | 31 | $33.5M |
| Q2 2023 | 32 | $41.9M |
| Q1 2023 | 32 | $51.0M |
| Q4 2022 | 28 | $42.8M |
| Q3 2022 | 29 | $48.3M |
| Q2 2022 | 33 | $52.2M |
| Q1 2022 | 41 | $132.7M |
| Q4 2021 | 42 | $303.1M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Xilio Therapeutics, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Qube Research & Technologies Ltd | 4 | $4 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 108 | $117 | 0.00% | +2+1.9% | Added |
| UBS Group AG | 201 | $217 | 0.00% | 00.0% | Unchanged |
| Key Financial Inc | 830 | $896 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 533 | $1.00K | 0.00% | +65+13.9% | Added |
| JPMorgan Chase & Co | 2,744 | $2.96K | 0.00% | −113−4.0% | Reduced |
| Tower Research Capital LLC (TRC) | 11,153 | $12.0K | 0.00% | −2,822−20.2% | Reduced |
| Charles Schwab Investment Management Inc | 11,925 | $12.9K | 0.00% | 00.0% | Unchanged |
| Dunhill Financial, LLC | 10,274 | $15.7K | 0.01% | 00.0% | Unchanged |
| State Street Corp | 15,690 | $16.9K | 0.00% | 00.0% | Unchanged |
| Summit Trail Advisors, LLC | 16,000 | $17.3K | 0.00% | +16,000 | New |
| Northern Trust Corp | 17,798 | $19.2K | 0.00% | 00.0% | Unchanged |
| FNY Investment Advisers, LLC | 27,500 | $29.0K | 0.02% | +27,500 | New |
| Prelude Capital Management, LLC | 29,500 | $31.9K | 0.00% | +29,500 | New |
| PFG Investments, LLC | 30,000 | $32.4K | 0.00% | +30,000 | New |
| SevenBridge Financial Group, LLC | 31,000 | $36.6K | 0.01% | +31,000 | New |
| BlackRock Inc. | 45,355 | $49.0K | 0.00% | −1,507−3.2% | Reduced |
| Millennium Management LLC | 70,198 | $75.8K | 0.00% | +39,847+131.3% | Added |
| Bridgeway Capital Management, LLC | 71,081 | $76.8K | 0.00% | −84,400−54.3% | Reduced |
| Geode Capital Management, LLC | 84,826 | $91.7K | 0.00% | 00.0% | Unchanged |
| FIL Ltd | 218,705 | $236.2K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 221,905 | $239.7K | 0.00% | +94,640+74.4% | Added |
| Renaissance Technologies LLC | 249,446 | $269.0K | 0.00% | +39,746+19.0% | Added |
| Balyasny Asset Management LLC | 338,542 | $365.6K | 0.00% | +338,542 | New |
| Vanguard Group Inc | 902,531 | $974.7K | 0.00% | 00.0% | Unchanged |
| Atlas Venture Life Science Advisors, LLC | 992,912 | $1.07M | 0.10% | −1,766,432−64.0% | Reduced |
| Rock Springs Capital Management LP | 1,440,759 | $1.56M | 0.04% | 00.0% | Unchanged |
| RiverVest Venture Management LLC | 1,441,444 | $1.56M | 19.12% | 00.0% | Unchanged |
| Takeda Pharmaceutical Co Ltd | 1,475,121 | $1.59M | 0.55% | 00.0% | Unchanged |
| FMR LLC | 1,907,671 | $2.06M | 0.00% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 2,805,413 | $3.03M | 0.24% | 00.0% | Unchanged |
| Octagon Capital Advisors LP | 0 | $0 | 0.00% | −1,785,000−100.0% | Sold out |
| Artal Group S.A. | 0 | $0 | 0.00% | −450,000−100.0% | Sold out |
| Laurion Capital Management LP | 0 | $0 | 0.00% | −116,847−100.0% | Sold out |
| ArrowMark Colorado Holdings LLC | 0 | $0 | 0.00% | −83,373−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −51,419−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −10,763−100.0% | Sold out |
| Cullen/Frost Bankers, Inc. | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −11−100.0% | Sold out |
| Trustees of Columbia University in the City of New York | – | – | – | – | Not filed |